Management of Portal Hypertension: From Considerations in MASLD and the Assessment of Frailty
Nov
10
2025
Convention Center: Room 202, Level 2
2:00 PM
- 3:30 PM
World Class Speakers
Description
Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.Journey Maps
Presentations
2:00 PM
- 2:15 PM
Aug
05
2026
Convention Center - Room 202, Level 2
Development and internal validation of the Laboratory-based Liver Frailty Index (Lab-LFI)—a prediction model based on circulating biomarkers for frailty in patients with cirrhosis
Jasmohan S. Bajaj, MD, FAASLD
, Abstract Presenter
Cirrhosis and Portal Hypertension
2:30 PM
- 2:45 PM
Aug
05
2026
Convention Center - Room 202, Level 2
Frailty, Cognitive Impairment and Comorbid Conditions add to Cirrhosis Severity in Prediction of 12-month Hospitalizations in a Multi-center Outpatient Cirrhosis Cohort
Jasmohan S. Bajaj, MD, FAASLD
, Abstract Presenter
Cirrhosis and Portal Hypertension
2:45 PM
- 3:00 PM
Aug
05
2026
Convention Center - Room 202, Level 2
Prognostic role of HVPG and non-invasive tests across the spectrum of advanced steatotic liver disease
Jasmohan S. Bajaj, MD, FAASLD
, Abstract Presenter
Cirrhosis and Portal Hypertension
3:00 PM
- 3:15 PM
Aug
05
2026
Convention Center - Room 202, Level 2
Belapectin Reduces Liver Stiffness Progression and Prevents Varices at 18 Months in MASH Cirrhosis: Results from the NAVIGATE Trial
Raj Vuppalanchi, MD, FAASLD
, Abstract Presenter
Cirrhosis and Portal Hypertension
Objectives
- Summarize the importance of frailty assessment in patients with cirrhosis